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Abstract
Hepatosplenic T-cell lymphoma is a rare form of non-Hodgkin lymphoma, which carries a poor prognosis. We
report our single-institution experience in the management of hepatosplenic T-cell lymphoma (HSTCL)- in 14
patients (pts) among whom 7 who remain alive (50%) and in remission at a median follow-up of 66 months.
More frequent long-term survival was seen in those treated with a non-CHOP (cyclophosphamide/doxorubi-
cin/vincristine/prednisone) induction and consolidative stem cell transplant (SCT).
Introduction: Hepatosplenic T-cell lymphoma is a rare form of extranodal non-Hodgkin lymphoma, first recognized
as a distinct entity in the Revised European-American Lymphoma classification. Typical presentation includes
lymphomatous infiltration of spleen and liver, and peripheral lymphadenopathy is rarely seen. The prognosis is almost
uniformly poor, and there are no prospective studies of treatment of HSTCL. Patients and Methods: For this report,
we conducted a retrospective review of all pts who underwent treatment for HSTCL at our institution. Individual
chart review was performed to report clinical presentation, management, and outcome. Results:We identified 14
pts with HSTCL managed at our center, 7 of which remain alive with median follow-up of 65.6 months. Six of 7
received alternative induction chemotherapy regimens such as ICE (ifosfamide, carboplatin, etoposide) or IVAC
(ifosfamide, etoposide, high-dose cytarabine) as opposed to CHOP and all surviving pts had proceeded to
undergo either autologous or allogeneic SCT. Conclusion: Our results suggest that use of non-CHOP induction
regimen and early use of high dose therapy and SCT consolidation may translate to improved survival for pts with
HSTCL.
Clinical Lymphoma, Myeloma & Leukemia, Vol. 13, No. 1, 8-14 © 2013 Elsevier Inc. Open access under CC BY-NC-ND license.
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Described first by Farcet et al in 1990,1 hepatosplenic T-cell lym-
phoma (HSTCL) is a distinct lymphoma entity with unique clinico-
Memorial Sloan-Kettering Cancer Center, New York, NY
Submitted: Jun 14, 2012; Revised: Aug 31, 2012; Accepted: Sep 14, 2012; Epub: Oct
27, 2012
Address for correspondence: Steven M. Horwitz, MD, Memorial Sloan-Kettering
Cancer Center, 1275 New York Ave, New York, NY 10021
Fax: 646-422-2164; e-mail contact: horwitzs@mskcc.org
nical Lymphoma, Myeloma & Leukemia February 2013pathologic features and poor clinical outcome, which has been rec-
ognized in the revised European-American Lymphoma classification
in 19942 and in the subsequent World Health Organization
classifications.3–7
Hepatosplenic T-cell lymphoma can occur at any age but is most
often seen in teenagers or young adults, with a strong male predom-
inance.1,8–12 It is an extremely rare lymphoma making up 5% of
peripheral T-cell lymphomas.5,12 Immunocompromised patients are
overrepresented, with reports of HSTCL developing during long-
term immunosuppression after solid-organ transplant13–15 and in
2152-2650 © 2013 Elsevier Inc.
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athe setting of other immune dysregulation includingmalignancy and
infection.16,17 The importance of iatrogenic immunosuppression as
a contributor to lymphomagenesis has become particularly relevant
in light of increased incidence of HSTCL in patients with chronic
inflammatory diseases after treatment with immunosuppressants,
specifically agents blocking tumor necrosis factor (TNF)- and/or
hiopurine agents.18–24
Occurrence is predominant in young male adults, who typi-
cally present with hepatosplenomegaly and peripheral blood cy-
topenias, especially thrombocytopenia. B-symptoms are com-
mon, whereas peripheral lymphadenopathy is usually absent.
Patients are most frequently diagnosed after splenectomy and/or
liver biopsy, although bone marrow biopsy with an appropriate
immunophenotype in this clinical setting might be sufficient to
make the diagnosis.4,25 On pathologic review, neoplastic cells are
ommonly found in the red pulp of the spleen and show a pref-
rence to infiltrate the splenic, hepatic, and bone marrow sinu-
oids.11,26 The immunophenotype typically is a CD4/CD8
T-cell with CD2 and CD3 expression. Other markers such as
D5, CD25, TIA-1, and granzyme B are usually absent. NK cell
arkers, such as CD56 and CD16 might be expressed.4,5,12,25,26
The malignant cells most often express a / T-cell phenotype as
an be demonstrated by flow cytometry, and as such  F-1 stain-
ng is not found.5,11 Reports have described similar clinical pre-
sentations with tumor cells expressing an -phenotype,27,28 and
Table 1 Clinical Presentation
Patient
Number Age/Sex HM SM LAN B-Sx Hgb Pltl
1 46/M Yes Yes No Yes Yes Yes
2 34/M Yes Yes No Yes Yes No
3 51/M Yes Yes No Yes Yes Yes
4 23/M Yes Yes No Yes Yes Yes
5 37/M Yes Yes No Yes No Yes
6 59/M Yes No Yes Yes Yes No
7 12/M No Yes Yes Yes Yes No
8 19/M No Yes No No Yes No
9 48/M Yes Yes Yes Yes No Yes
10 53/M No Yes Yes Yes Yes No
11 50/M Yes Yes No Yes Yes Yes
12 22/M Yes Yes Yes Yes Yes Yes
13 27/M Yes Yes No Yes Yes Yes
14 18/M Yes Yes No Yes Yes Yes
Listed for all 14 patients are clinical, laboratory, and pathologic variables at the time of diagnos
Abbreviations: 6-MP 6-mercaptopurine; BM bone marrow involvement; B-Sx presence
in pathologic specimen; Hgb  decreased hemoglobin; HM hepatomegaly; HTN hyperten
rthritis; LAN lymphadenopathy; LDH elevated lactate dehydrogenase; LFT abnormal li
vascular disease; SM splenomegaly; UC ulcerative colitis; WBC abnormal leukocyte coare considered an immunophenotypic variant of the same diseaseentity in the World Health Organization classification. The T-
cell receptor (TCR)  gene is always clonally rear-
anged4,5,12,25,26; the T-cell  gene might be rearranged as well.4
Cytogenetic evaluation frequently demonstrates isochromosome
7q although this is not specific for this disease.29–32
In the literature, the prognosis of HSTCL is almost uniformly
poor, and no prospective trials investigating treatment ap-
proaches are reported. Most of the published data consists of case
reports and series, with 2 larger single-institution series focused
on treatment outcome, demonstrating exceedingly poor long-
term therapeutic results with a CHOP (cyclophosphamide/doxo-
rubicin/vincristine/prednisone)-based regimen.25,33 Anecdotal
ctivity of several other chemotherapy regimens has been reported
n form of case reports.34–39 Several authors have published ex-
periences with high-dose therapy (HDT) autologous or allogeneic
stem cell transplantation (SCT),11,12,25,33,40–46 and a 2007 col-
ection of published case reports of HSTCL treated with alloge-
eic stem cell transplantation suggests a better outcome for that
pproach.47
Patients and Methods
To investigate our center’s experience in the management of
HSTCL, we conducted a search using our T-cell lymphoma and
bone marrow transplant databases. Included in this report were all
patients treated at Memorial Sloan-Kettering Cancer Center with a
C LDH LFT BM EBV Comorbidities IS-Therapy
Yes Yes No Yes None No
Yes Yes Yes NA UC 6-MP
Yes Yes Yes Yes HTN, DM,Emphysema No
Yes Yes No NA jRA Unclear
Yes Yes No NA UC Seminoma 6-MP
NA NA No NA PVD No
No No Yes No Asthma No
Yes Yes Yes NA None No
Yes Yes Yes NA jRA No
NA NA Yes NA Depression No
Yes Yes Yes NA CD Infliximab, 6-MP
Yes Yes Yes NA CD 6-MP
Yes Yes Yes NA CD Adalimumab,6-MP
No No Yes NA CD Infliximab, 6-MP
orbidities, and previous immunosuppressive therapy.
ptoms; CD Crohn’s disease; DM diabetes mellitus; EBV evidence of Ebstein Barr virus
-Therapy prior immunosuppressive therapy other than steroids; jRA  juvenile rheumatoid
tion tests; M male; NA not assessed; Pltl decreased platelet count; PVD peripheralWB
No
Yes
No
Yes
No
No
Yes
Yes
Yes
Yes
Yes
No
No
Yes
is, com
of B-sym
sion; IS
ver func
unt.diagnosis ofHSTCL, for whom follow-up information was available.
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10 CThis report summarizes our single-center experience with 14 con-
secutive patients treated between the years of 1994 and 2012. We
reviewed each patient’s records for characteristics of initial clini-
cal presentation, the immunohistochemistry of lymphomatous
cells, treatment regimen, and responses. Sufficient data to calcu-
late an International Prognostic Index (IPI)48 and prognostic in-
ex for peripheral T-cell lymphoma (PIT)49 were available for 12
f 14 subjects with 2 patients missing lactate dehydrogenase
LDH) values at time of diagnosis. Kaplan–Meier curves were
alculated to determine overall survival (OS) and progression-free
urvival (PFS). Log-rank 2 test was used to compare the effect of
clinical variables on survival.
Results
Patient Characteristics
All patients were male with amedian age of 36 years (range, 12–59
years, see also Table 1). All subjects had stage IV disease with hepa-
Table 2 Treatment Summary and Response to Therapyb
Patient
Number
Time to
Treatment
Start (Months)
Removal of
Spleen
Induction
Regimen
Respon
Induct
1 10 Yes ICE 3 CR
2 2 No IVAC 4 CR
3 6 Yes IVAC 4 POD
4 6 Yes ICE 3 PR
5 4 Yes CHOP 2 POD
6 1 Yes CHOP 1 PR
7 3 Yes Pentostatin POD
8 4 Yes 2CDA 2 POD
9 2 No CHOP 4 PR
10 4 Yes CHOP 6 CR
11 1 No ICE 4 PR
12 1 No ICE 4 POD
13 2 No IVAC 4 CR
14 4 No Pediatric ALL inductionthen IVAC 2 CR
Listed for all 14 patients are initial chemotherapy regimens with response; further management
survival, and vital status at the time of analysis. Time to treatment start indicates time interval b
Abbreviations: 2CDA 2-chlorodeoxyadenosine/cladribine; ALL acute lymphoblastic leukem
usulfan, melphalan, fludarabine; CHOP cyclophosphamide/doxorubicin/vincristine/prednison
nfusion; DOD died of disease; DOT treatment-related death; EPOCH etoposide, vincris
CE ifosfamide, carboplatin, etoposide; IPI International Prognostic Index; IVAC ifosfamid
response evaluable; NYII high dose cytarabinec, daunorubicin, PEG asparaginase, cyclophosp
lymphoma; POD progression of disease; PR partial response; Rx treatment; TBI tota
a Response unclear, treatment received at outside institution.
b Incomplete clinical information to fully determine score.tomegaly and/or splenomegaly. Ten of 14 cases (71%) had docu-
linical Lymphoma, Myeloma & Leukemia February 2013mented bone marrow involvement, 10 of 12 patients (91%) had
elevated LDH, and all but 1 had B symptoms. Thrombocytopenia
was present at diagnosis in 9 of 14 patients (64%), anemia in 12 of 14
patients (86%), and leukopenia in 6 of 14 patients (43%). Transami-
nases and/or alkaline phosphatase were elevated in 10 of 14 patients
(71%). Eight of 14 cases (57%) had previous autoimmune disease: 2
with ulcerative colitis, 4 with Crohn’s disease, and 2 with juvenile
rheumatoid arthritis. Three patients had received both anti-TNF
therapy (2, infliximab; 1, adalimumab) and 6-mercaptopurine (6-
MP); 3 had been treated only with 6-MP. Risk stratification per IPI
and PIT are summarized in Table 2.
Clinical Outcomes
Responses to induction regimens were CHOP (complete re-
mission [CR], 1; partial response [PR], 2; progression of disease
[POD], l), ICE (ifosfamide, carboplatin, etoposide)/IVAC (ifos-
famide, etoposide, high-dose cytarabine) (CR, 4; PR, 2; POD, 2),
urther Regimen
(Pre-Txp)
Auto or
Allo
Status at
Time of Txp Conditioning Regimen
None Allo CR Melphalan, fludarabine,campath
None Auto CR Etoposide,cyclophosphamide, TBI
EPOCH 2 Allo CR TBI, thiotepa,cyclophosphamide
None Allo PR Bus/mel/flu, splenic XRT,equine ATG
ICE 5 Auto CR BEAM
ICE 4 Auto CR Cyclophosphamide,carmustine, etoposide
YII–POD; topotecan/
vinorelbine/thiotepa Allo PR
Thiotepa, cyclophosphamide,
TBI, ATG
CHOP 3-POD; ICE
 2 Allo PR TBI, cyclophosphamide
ICE-POD; EPOCH
2 — NA NA
ICE Auto CR BEAM
EPOCH 1-POD;
pentostatin 4 — NA NA
None — NA NA
Campath 1 Allo CR Thiotepa, cyclophosphamide,TBI
None Allo CR Etoposide, TBI
g subsequent chemotherapy and transplant approach; risk stratification per IPI and PIT; overall
the onset of symptoms and start of induction.
 antithymocyte globulin; BEAM carmustine, etoposide, ara-C, melphalan; Bus/mel/flu
 cyclophosphamide, idarubicin, etoposide; CR complete response; DLI donor leukocyte
xorubin, cyclophosphamide, prednisone; H high; HD high dose; HI high intermediate;
oside, high dose cytarabine; L low; LI low intermediate; MTX methotrexate; NRE no
, HD MTX, vincristine; OS overall survival; PEG pegylated; PIT index for peripheral T-cell
irradiation; TLR7 toll-like receptor 7; Txp transplant.se
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Martin H. Voss et alCHOP received ICE as second-line therapy, 2 of 3 achieved a CR.
One patient received ICE as consolidation after obtaining a CR to
CHOP before proceeding to SCT. Eleven of 14 patients achieved
at least a PR and proceeded to HDT-SCT. Four patients received
an autologous SCT, and 8 patients an allogeneic SCT (1 as a
second graft after relapse from autologous SCT). At the time of
this report, 7 of 14 patients are alive, 3–149 months from the time
of diagnosis; the 7 surviving patients all underwent HDT-SCT.
Six of these remain in remission, 1 relapsed 1 year after alloge-
eic SCT, had been re-treated successfully with donor leukocyte
nfusions, but has since again relapsed. A total of 8 patients re-
eived ICE or IVAC as part of initial therapy and 5 of 8 are alive.
nly 2 of 6 patients remain alive among those treated with other
nitial regimens and both surviving patients received ICE as part
f consolidation before HDT-SCT. After autologous-SCT, 2 of 4
atients relapsed at 5 and 35 months. Moreover, after allogeneic-
CT 2 of 7 patients relapsed at 3 and 6 months. Two of 8 patients
ndergoing allo-SCT died of treatment-related toxicities. With a
edian follow-up time of 66 months, median PFS and OS for the
ntire cohort are 13.3 months (range, 2.4 –148) and 59 months
range, 4 –150 months), respectively (Figure 1).
Complete information to calculate respective prognostic in-
exes (IPI or PIT) were available for 12 of 14 patients. A corre-
ation with outcome could not be found for either of the 2. Three
Table 2 Continued
Patient
Number
CD34 Dose
( 106/kg)
Response to
Txp
Relapse, After
Txp (Months)
Fu
1 9.4 CR 6
2 10 CR —
3 27.4 CR —
4 14.3 SD 3
5 2.58 CR 5
6 2.8 CR 25
7 9.91 CR 3 TLRcyc
8 Unclear CR —
9 NA NA NA
10 4.5 CR —
11 NA NA NA
12 NA NA NA
13 8.02 CR NA
14 8.01 NRE NAf 4 patients with an IPI of low to low-intermediate risk (0 –2factors) remain alive compared with 3 of 8 patients with IPI
high-intermediate to high-risk disease (3 factors) (P  .267)
(Figure 2). For the PIT, all 12 patients had at least 1 risk factor: 6
of 10 patients with a PIT of 1–2 are alive versus 0 of 2 patients for
PIT of 3 (P  .117).
Discussion
Management of HSTCL is challenging, and historically, out-
come has almost uniformly been poor. There are no prospective
trials to provide guidance for the treatment of this disease, and
most of the current literature consists of case reports or case re-
view series. Chemotherapy regimens employed in other series
include CHOP and CHOP-like regimen,25 alemtuzumab/
ladribine,34 hyperCVAD,35 fludarabine/alemtuzumab,36 IEV
(ifosfamide, epirubicin, and etoposide),37 and pentostatin.38,39
Several authors suggest superior outcome with the addition of
HDT-SCT, and a number of reports include cases treated suc-
cessfully with autologous and allogeneic SCT.11,12,25,33,40–47
There are only 2 reports of larger single-center experiences in the
literature thus far. The first was published by Belhadj and col-
leagues in 2003 and includes data from 21 patients with HSTCL
diagnosed between 1981 and 2001.25 In their report, most pa-
tients (90.5%) received induction treatment with CHOP or
CHOP-like regimens, and 2 of 21 subjects (9.5%) were induced
Treatment
t Txp
Response to
Further Rx IPI PIT
OS From
Induction
(Months)
Status
DLI CR 3 (HI) 1 50.5 Alive
— NA 3 (HI) 2 57.7 Alive
— NA 3 (HI) 3 9.9 DOT
Allo CR 2 (LI) 1 66.0 Alive
CIE Uncleara 3 (HI) 2 21.7 DOD
 3, Allo PR NAb NAb 59.2 DOT
ist, fludarabin
phamide, DLI POD 1 (L) 0 13.1 DOD
— NA 1 (L) 2 149.6 Alive
NA NA 4 (H) 3 5.9 DOD
— NA NAb NAb 23 Alive
NA NA 3 (HI) 2 4 DOD
NA NA 3 (HI) 2 5.7 DOD
NA NA 3 (HI) 2 4.7 Alive
NA NA 2 (LI) 1 3 Aliverther
Pos
CHOP
7 agon
lophosusing platinum cytarabine-based therapy. Seven of 21 patients
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12 C(33.3%) failed to respond to induction, all died within 16
months. Nine of 21 patients (43%) achieved a CR, 5 of 21 pa-
tients (24%) a good PR, the latter including patients induced
Figure 1 Progression-Free Survival and Overall Survival.
Kaplan-Meier Curve of Progression-Free Survival
and Overall Survival in Our Cohort
1.0
0.8
0.6
OS: 7 events; 7 censored
PFS: 9 events; 5 censored
0.4
0.2
0.0
0 24 48 72
Time in Months
Cu
m
ul
at
iv
e 
Su
rv
iv
al
96 120 144
Figure 2 Survival per IPI. Kaplan-Meyer Curve Stratified in
Groups with International Prognostic Index (IPI) 0–2
Versus 3–5 Demonstrating No Significant Difference
in Overall Survival
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96 120 144with non-CHOP regimen. Nine of 21 patients (43%) went on to
linical Lymphoma, Myeloma & Leukemia February 2013either allogeneic bone marrow transplantation (3 of 21 pa-
tients—2 died of treatment-related disease, 1 with POD) or au-
tologous bone marrow transplantation (6 of 21 patients (28.6%),
4 of which died within 13–33 months). Despite response to in-
duction treatment in two-thirds of the treated patients, long-term
therapeutic results were poor with a median survival of 16
months. At the time of report only 2 of 21 patients (9.5%) were
alive; both had received induction treatment with platinum/
cytarabine with PR and gone on to autologous bone marrow
transplant. More recently, Falchook and colleagues published
their single-center experience on 14 patients with HSTCL treated
at M.D. Anderson Cancer Center between 1997 and 2007.33
Despite CR rates of 50% with various induction regimens, the
duration was short-lived in most cases, and median survival was 8
months. Similar to other reports, all patients treated with CHOP-
like regimen (6 of 14) did poorly. The 4 patients (29%) that were
alive at the time of report (11–36 months) had been induced with
more intense regimen, 3 of 4 survivors had been consolidated
with allogeneic SCT. From these data the authors attempted to
identify possible clinical characteristics to help predict outcome.
Sex was the only factor conferring a statistically different survival
(median OS 25 months in female vs. 8 months in male patients).
There were trends suggesting better survival in patients with
TCR rearrangements in the  chain with all 4 patients with such
earrangement achieving CR and still alive in remission, though
tatistically nonsignificant trends toward worse survival were seen
ith liver involvement at diagnosis (median OS 7.5 vs. 13 months
ithout liver involvement) and history of prior immunocompro-
ise (median OS 6 vs. 11 months without prior immunocom-
romise). No trends in OS were seen for age, presence of B-
ymptoms, or cytopenias at presentation, TCR status, or
ytogenetics.
Our single-institution experience further supports the notion
hat use of non-CHOP induction chemotherapy regimens such as
CE or IVAC and early HDT-SCT consolidation might improve
he outcome for patients with HSTCL compared with reported
esults with CHOP or CHOP-like regimens alone. At the time of
his report, 7 of 14 patients (50%) remain alive, 5 of which were
nitially treated with non-CHOP regimen. All 7 surviving pa-
ients had preceded to HDT-SCT, 5 receiving an allogeneic, and
an autologous graft. Both patients treated with autologous SCT
ere in CR at the time of transplant, while 2 of 5 recipients of
llogeneic grafts received transplant in PR. The 3 patients that did
ot undergo SCT as part of their management did poorly (see also
igure 1).
When applying the prognostic factors suggested by Falchook
nd colleagues, our data do not confirm a trend toward worse OS
n patients with liver involvement at the time of diagnosis (P 
382), nor improved OS in patients with  TCR rearrangements
P .919) or previous history of immunosuppression (P .455).
ormally established scoring models used to assess prognosis in
eripheral T-cell lymphoma include the IPI48 and the PIT.49
These systems might not be as useful for stratifying patients with
HSTCL because those affected are almost universally young with
stage IV disease. As noted above, we were unable to show corre-
lation with outcome for either of the 2 prognostic models, bearing
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Martin H. Voss et alin mind the limitations of our sample size. Notably, for patients
who are not estimated among the highest risk at initial prese-
ntation (PIT  3; IPI  3) our data show long-term survivors
mong those consolidated with autologous as well as allogeneic
CT.
Serial reports of HSTCL in patients receiving immunosuppres-
ive therapy with agents blocking TNF- have prompted a safety
lert through the US FDA, originally issued in 2009 and recently
pdated.50 An increase in incidence has also been reported
ith other immunosuppressants such as azathioprine, or 6-
P.24,51–53 The contribution of the underlying autoimmune dis-
ase itself is less well established for inflammatory bowel dis-
ases54 than for autoimmune arthritis.55 In our series, 8 of 14
atients carried a diagnosis of autoimmune disease, 6 of which
ere treated with systemic immunosuppressants other than cor-
icosteroids. Only 3 had received previous TNF- blockade,
which was given sequentially or in combination with 6-MP. The
other 3 patients had been treated with 6-MP alone. Two patients
with a previous diagnosis of autoimmune disease had no docu-
mented history of such immunosuppression, but for 1 of them
previous treatment records for juvenile arthritis were unavailable
to our review.
Conclusion
Our choice of transplant approach has largely been guided by
the availability of a suitable donor. Though our series is clearly
too small to draw definitive conclusions our preference is for
allogeneic SCT. However, our experience suggests HDT and con-
solidation with autologous SCT represents a reasonable alterna-
tive for those who can achieve a CR to their initial chemotherapy.
Certainly for patients without a suitable allogeneic donor, this is
our preferred approach.
As a case series, this study’s principal limitations are the small
number of subjects and its retrospective nature. It certainly cannot
dissect the relative importance of the individual components of ther-
apy (non-CHOP induction vs. HDT consolidation). In the absence
of prospective trials for this very rare disease, it might however pro-
vide guidance in the treatment of these young patients with no es-
tablished standard of care.
Clinical Practice Points
● Hepatosplenic T-cell lymphoma typically presents with infiltra-
tion of spleen and liver and rarely involves nodal regions.
● A history of inflammatory bowel diseasemight predispose patients
to the development of HSTCL; the use of TNF- antagonist or
6-MP analogs might also increase this risk.
Of the 14 patients in our study, 7 remain alive; 6 received non–
CHOP-based induction therapies (ICE or IVAC).
All patients who remained without evidence of disease underwent
consolidative transplantation.
In our experience, consideration of a non–CHOP-based induction
therapywith intent to consolidate with an allogeneic SCT in first CR
appears to be a necessity considering the high propensity of primary
refractory or short interval relapse associated with HSTCL.Disclosures
The authors have stated that they have no conflicts of interest.
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